Research Vision
Decoding Biological Mechanisms Through Cohort Multi-Omics
We use cohort-based multi-omics to connect clinical phenotypes with the biological mechanisms that shape human health and disease—turning population-level discoveries into testable mechanistic insights.
About Me
This is the personal website of Xin Zhou and an introduction to his laboratory and research program. Xin Zhou (周欣), Ph.D., is a tenure-track Principal Investigator at the Intelligent Medicine Institute, Fudan University, where he has led an independent research program since 2025. He also holds a joint appointment as Professor at the Hong Kong PolyU–Stanford Joint Research Center. He completed his Ph.D. training with Dr. George Weinstock in 2019 and his postdoctoral training with Dr. Michael Snyder in 2024. His interdisciplinary research integrates microbiome science, multi-omics, artificial intelligence, statistical modeling, organoid systems, and disease biology to advance precision medicine.
Research Interests
AI-Enabled Microbiome & Multi-Omics
We develop artificial intelligence and statistical frameworks for microbial database mapping, collinearity analysis, power estimation, and longitudinal multi-omics integration. These approaches reveal stable and individualized host–microbiome patterns across body sites and support rigorous, reproducible precision-medicine studies.
Organoid & Animal Models for Microbe–Immune Interactions
We build immune organoids and complementary animal models to investigate how microbial strains shape human immune and physiological responses. These experimental systems enable mechanistic testing of candidate microbes and support the development of precise microbial interventions for metabolic and inflammatory diseases.
Inflammation, PAH & Precision Medicine
We combine single-cell transcriptomics, immunomics, metabolomics, lipidomics, and microbiome profiling to define disease mechanisms in pulmonary arterial hypertension and other chronic inflammatory conditions. Current work examines host responses to HERV-K and oral-microbiome signals associated with systemic disease, with the goal of identifying actionable biomarkers and therapeutic pathways.
